Menu
/REGISTER
Montecito
Tolman Wiker
Pac Premier
Fielding
Farmers merchants
Nixon Peabody
Express Pros
Loading...
You are here:  Home  >  Health Care  >  Current Article

Amgen bipolar about biosimilars

By   /   Friday, December 4th, 2015  /   Comments Off on Amgen bipolar about biosimilars

    Print       Email
Amgen co-founder William K. Bowes Jr. stands watch over the Thousand Oaks campus. Call it Amgen’s competition conundrum. Biosimilar drugs are a new class of medicine that Amgen could develop and reap great rewards but the Thousand Oaks-based biotech giant also could lose billions of dollars if competitors develop biosimilars for Amgen’s blockbuster drugs. Biosimilars…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Biotech firm Arcutis gets $94.5M in funding round

Read More →